Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Co.'s product candidates are derived from donor cells and pre-manufactured, stored frozen and ship to a patient's treatment location. Co.'s lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. The ARTV average annual return since 2024 is shown above.
The Average Annual Return on the ARTV average annual return since 2024 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ARTV average annual return since 2024 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ARTV average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|